Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
3-beta-hydroxysteroid dehydrogenase (3β-HSD) is a crucial enzyme in steroid hormone biosynthesis. It catalyzes the oxidative conversion of Δ5-3β-hydroxysteroids to Δ4-3-ketosteroids, an essential step for producing all classes of active steroid hormones, including progesterone, glucocorticoids, mineralocorticoids, androgens, and estrogens. There are two main human isoforms: HSD3B1 (expressed mainly in placenta and peripheral tissues) and HSD3B2 (predominantly expressed in adrenal gland and gonads). Mutations in HSD3B2 cause congenital adrenal hyperplasia due to impaired steroidogenesis.
Inhibition of 3β-HSD activity, thereby blocking the production of steroid hormones such as progesterone, glucocorticoids, mineralocorticoids, androgens, and estrogens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 3-beta-hydroxysteroid dehydrogenase (3β-HSD).